Clinical Trial Update: Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer [Phase 3]

View source ↗

Summary

Updates on a Phase 3 trial evaluating antiandrogen withdrawal as a treatment strategy for hormone-refractory prostate cancer. Sponsored by the Alliance for Clin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Nilutamide (Nilutamide)
• bicalutamide (bicalutamide)
• flutamide (flutamide)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED